

FORM 51-102F3

MATERIAL CHANGE REPORT

1. Name and Address of Company

CardioComm Solutions, Inc.
259 Yorkland Road, Suite 200
Toronto, ON M2J 0B5

2. Date of Material Change

May 15, 2013

3. News Release

The news release announcing the material change was disseminated on May 21, 2013, through StockNetworkMedia. The news release was also filed with the British Columbia, Alberta and Ontario Securities Commissions on SEDAR.

4. Summary of Material Change

CardioComm Solutions, Inc. today announced that the Company has issued 29,201 shares to Mr. Simi Grosman, an independent member of the board of directors, for services rendered to the Company in the months of January, February and March of 2013. The shares were issued at a 5% premium to the closing price of the Company's shares at the end of each month. The total value of the shares issued was \$4,500; the shares were issued pursuant to a services agreement dated January 11, 2013. The shares are subject to a four month hold period which will expire on September 16, 2013.

5.1 Full Description of Material Change

See attached news release.

5.2 Disclosure for Restructuring Transactions

N/A

6. Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable.

7. Omitted Information

No information has been intentionally omitted from this material change report.

8. Executive Officer

Etienne Grima, CEO, 1-877-977-9425

9. Date of Report

May 23, 2013

FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG

May 21, 2013

CardioComm Solutions Issues Shares in Support of Expanded HeartCheck™ Sales and Marketing Efforts in North America.

TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX-V: EKG) ("CardioComm Solutions" or the "Company") today announced that the Company has issued 29,201 shares to Mr. Simi Grosman, an independent member of the board of directors, for services rendered to the Company in the months of January, February and March of 2013. The shares were issued at a 5% premium to the closing price of the Company's shares at the end of each month. The total value of the shares issued was \$4,500; the shares were issued pursuant to a services agreement dated January 11, 2013. The shares are subject to a four month hold period which will expire on September 16, 2013.

"In response to growing interest in our medical devices from international distributors, Mr. Grosman has assumed an increased role in the management of our North American relationships," confirmed Etienne Grima, CEO of CardioComm Solutions. "With anticipated distributor sales and our now patent pending SMART Monitoring 30 minute ECG reporting service moving forward, now is the prudent time to develop a dedicated North American sales and marketing lead."

About CardioComm Solutions

CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions, Inc. is headquartered in Toronto, Canada, with offices in Victoria, B.C.

FOR FURTHER INFORMATION PLEASE CONTACT:

Etienne Grima, Chief Executive Officer
1-877-977-9425
egrima@cardiocomm solutions.com
www.cardiocomm solutions.com

Forward-looking statements

This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.